Related Experiment Videos
Continuous infusion of coagulation factor products.
Joan M Stachnik1, Michael P Gabay
1Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street (M/C 886), Rm. 164, Chicago, IL 60612-7230, USA. stachnik@uic.edu
The Annals of Pharmacotherapy
|April 30, 2002
Summary
Continuous infusion of factor VIII and recombinant factor VIIa in hemophilia patients offers better hemostasis than bolus injections. This method maintains stable factor levels, reducing bleeding risks and consumption.
Area of Science:
- Hematology
- Pharmacokinetics
- Hemophilia Treatment
Background:
- Review of clinical data on continuous infusion factor products for hemophilia.
- Focus on factor VIII and recombinant factor VIIa in various clinical scenarios.
- Exploration of pharmacokinetic rationale, stability, and cost implications.
Observation:
- Continuous infusion leads to reduced factor clearance and sustained serum concentrations.
- Limited direct comparative trials exist; most compare with historical controls.
- Case reports and open-label trials form the primary data source.
Findings:
- Continuous infusion of factor products demonstrates superior hemostatic effects compared to intermittent bolus injections.
- Maintains consistent factor levels, minimizing bleeding risks from low trough concentrations.
- Reduced factor consumption observed due to decreased clearance with continuous infusion.
Implications:
- Continuous infusion represents a potentially more effective administration route for hemophilia patients.
- Extended stability of reconstituted products may offer practical advantages.
- Further research could validate long-term efficacy and cost-effectiveness.